Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  NASDAQ OMX STOCKHOLM  >  Swedish Orphan Biovitrum    SOBI   SE0000872095

SWEDISH ORPHAN BIOVITRUM (SOBI)
Mes dernières consult.
Most popular
  Report  
 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Stockholm
04/19/2018 04/20/2018 04/23/2018 04/24/2018 04/25/2018 Date
157.45(c) 159.75(c) 161.3(c) 160.85(c) 158.95 Last
599 323 627 663 733 494 771 246 577 509 Volume
-0.60% +1.46% +0.97% -0.28% -1.18% Change
More quotes
Financials (SEK)
Sales 2018 8 179 M
EBIT 2018 2 466 M
Net income 2018 1 846 M
Finance 2018 2 970 M
Yield 2018 0,26%
Sales 2019 9 320 M
EBIT 2019 3 132 M
Net income 2019 2 414 M
Finance 2019 5 084 M
Yield 2019 0,46%
P/E ratio 2018 23,13
P/E ratio 2019 17,72
EV / Sales2018 5,01x
EV / Sales2019 4,17x
Capitalization 43 955 M
More Financials
Company
Swedish Orphan Biovitrum AB engages as a biopharmaceutical company.It provides therapies and services for patients with rare diseases.The firm's core products include Kineret within the inflammation therapeutic area; and Orfadin, Ammonaps, and Ammonul within the genetics and metabolic therapeutic... 
Sector
Pharmaceuticals
Calendar
04/26 | 08:00amEarnings Release
More about the company
Surperformance© ratings of Swedish Orphan Biovitrum
Trading Rating : Investor Rating :
More Ratings
Latest news on SWEDISH ORPHAN BIOVITRUM
04/25SWEDISH ORPHAN BIOVITRUM : Invitation Presentation of Sobi's Q1 2018 results
AQ
04/19SWEDISH ORPHAN BIOVITRUM : Invitation - Presentation of Sobi's Q1 2018 results
AQ
04/17SOBI : Receives Approval from Health Canada for Once-Daily Dosing of Orfadin® (n..
BU
04/17SWEDISH ORPHAN BIOVITRUM : Sobi publishes 2017 Annual and Sustainability Report
AQ
04/16SWEDISH ORPHAN BIOVITRUM : Kineret approved in the EU for the treatment of Still..
AQ
04/11SWEDISH ORPHAN BIOVITRUM : Kineret® (anakinra) approved in the EU for the treatm..
AQ
04/04SWEDISH ORPHAN BIOVITRUM : Notice of annual general meeting in Swedish Orphan Bi..
AQ
04/03SWEDISH ORPHAN BIOVITRUM : Fredrik Wetterlundh joins Sobi™ as Head of Huma..
AQ
03/21SWEDISH ORPHAN BIOVITRUM : Sobi™ launches Ravicti® in Europe and advances ..
AQ
02/28SWEDISH ORPHAN BIOVITRUM : Sobi launches enhanced corporate sustainability initi..
AQ
More news
Sector news : Pharmaceuticals - NEC
04/25TAKEDA PHARMACEUTICAL : Health Care Up as Takeda-Shire Deal Looks Set -- Health ..
DJ
04/25Shire willing to back $64 billion Takeda bid, market signals doubts
RE
04/25INVESCO UK LTD INVESCO LTD. : Form 8.3 - Shire Plc
DJ
04/25GLAXOSMITHKLINE : 1Q Earnings Impacted by FX Effects -- Earnings Review
DJ
04/25Currency and pricing squeeze GSK as new shingles vaccine shines
RE
More sector news : Pharmaceuticals - NEC
Latest Tweets
04/19Swedish Orphan Biovitrum : Invitation - Presentation of Sobi's Q1 2018 Result.. 
04/10$SOBI Orphan Biovitrum AB Slightly Raising Our Sobi FVE Following Strong 201.. 
2017Swedish Orphan Biovitrum : Norbert Oppitz Joins Sobi(TM) as New Senior Vice P.. 
2017Myocarditis - Pipeline Review, H2 2017 Featuring CEL-SCI, GlaxoSmithKline &am.. 
2017Swedish Orphan Biovitrum : FDA grants SOBI003 Orphan Drug Designation for the.. 
More tweets
Qtime:77
News from SeekingAlpha
02/23Swedish Orphan Biovitrum AB ADR 2017 Q4 - Results - Earnings Call Slides 
02/23European advisory group backs expanded use for Swedish Orphan's Kineret 
01/23FDA signs off on Swedish Orphan's IND for MPS IIIA candidate SOBI003 
2017Bioverativ's Eloctate demonstrates positive effect on joints in hemophilia A .. 
2017Swedish Orphan Biovitrum AB ADR 2017 Q3 - Results - Earnings Call Slides 
Chart SWEDISH ORPHAN BIOVITRUM
Duration : Period :
Swedish Orphan Biovitrum Technical Analysis Chart | SOBI | SE0000872095 | 4-Traders
Technical analysis trends SWEDISH ORPHAN BIOVITRUM
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Average target price 152  SEK
Spread / Average Target -5,7%
EPS Revisions
Managers
NameTitle
Guido Oelkers President & Chief Executive Officer
Sven Håkan Björklund Chairman
Mats-Olof Wallin Chief Financial Officer & Senior Vice President
Marianne Keisu Chief Medical Officer & Vice President
Milan Zdravkovic Senior Vice President, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SWEDISH ORPHAN BIOVITRUM43.23%5 159
JOHNSON & JOHNSON-9.23%340 239
PFIZER1.60%218 908
NOVARTIS-8.06%203 482
ROCHE HOLDING LTD.-11.08%192 055
MERCK AND COMPANY6.79%162 398